PPBT – purple biotech ltd. - american depositary shares (US:NASDAQ)
Stock Stats
News
Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240
Purple Biotech (NASDAQ:PPBT) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
Purple Biotech (NASDAQ:PPBT) was downgraded by analysts at Wall Street Z
Form 6-K PURPLE BIOTECH LTD. For: Jan 12
Form 6-K PURPLE BIOTECH LTD. For: Jan 07
Form 6-K PURPLE BIOTECH LTD. For: Dec 16
Form 6-K PURPLE BIOTECH LTD. For: Dec 11
Form 6-K PURPLE BIOTECH LTD. For: Nov 19
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.